Jose Luiz Pedrini

TL;DR: The combination of pertuzumab plus trastuzumAB plus docetaxel, when used as first-line treatment for HER2-positive metastatic breast cancer, significantly prolonged progression-free survival, with no increase in cardiac toxic effects.

TL;DR: Pertuzumab and trastuzumAB without chemotherapy eradicated tumours in a proportion of women and showed a favourable safety profile, which justifies further exploration in adjuvant trials and support the neoadjuvant approach for accelerating drug assessment in early breast cancer.

TL;DR: Treatment with adjuvant trastuzumab for 1 year after chemotherapy is associated with significant clinical benefit at 4-year median follow-up and a substantial selective crossover of patients in the observation group to trastzumab was associated with improved outcomes for this cohort.

TL;DR: The primary endpoint (pathological complete response) was previously reported and secondary endpoints reported here are 5-year progression-free survival (analysed in the intention-to-treat population) and disease- free survival ( analysed in patients who had surgery).

TL;DR: Fulvestrant 500 mg was associated with a statistically significant increase in PFS and not associated with increased toxicity, corresponding to a clinically meaningful improvement in benefit versus risk compared with fulvestrant 250 mg.